1 MacKie RM, Bray CA, Hole DJ, Morris A, Nicolson M, Evans A, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002;360:587-91.

2 International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 55: solar and ultraviolet radiation. Lyon: International Agency for Research on Cancer; 1992.

3 Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997;73:198-203.

4 Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 2001;12:69-82.

5 Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW, et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001;44:837-46. [section 2.1] [section 2.3]

6 Hill L, Ferrini RL. Skin cancer prevention and screening: summary of the American College of Preventive Medicine’s practice policy statements. CA Cancer J Clin 1998;48:232-5.

7 Ferrini RL, Perlman M, Hill L. American College of Preventive Medicine Policy Statement: skin protection from ultraviolet light exposure. Am J Prev Med 1998;14:83-6.

8 Ness AR, Frankel SJ, Gunnell DJ, Smith GD. Are we really dying for a tan? BMJ 1999;319:114-6.

9 National Health and Medical Research Council. Clinical practice guidelines for the management of cutaneous melanoma. Canberra: The Council; 1999. [cited 16 May 2003]. Available from url: http://www.health.gov.au/nhmrc/publications/pdf/cp68.pdf [section 2.3] [section 4.3] [section 4.3.1]

10 Crane LA, Schneider LS, Yohn JJ, Morelli JG, Plomer KD. “Block the sun, not the fun”: evaluation of a skin cancer prevention program for child care centers. Am J Prev Med 1999;17:31-7.

11 Richard MA, Martin S, Gouvernet J, Folchetti G, Bonerandi JJ, Grob JJ. Humour and alarmism in melanoma prevention: a randomized controlled study of three types of information leaflet. Br J Dermatol 1999;140:909-14.

12 Dey P, Collins S, Will S, Woodman CB. Randomised controlled trial assessing effectiveness of health education leaflets in reducing incidence of sunburn. BMJ 1995;311:1062-3.

13 Hanrahan PF, Hersey P, Watson AB, Callaghan TM. The effect of an educational brochure on knowledge and early detection of melanoma. Aust J Public Health 1995;19:270-4.

14 Segan CJ, Borland R, Hill DJ. Development and evaluation of a brochure on sun protection and sun exposure for tourists. Health Educ J 1999;58:177-91.

15 Hanrahan PF, Hersey P, Menzies SW, Watson AB, D’Este CA. Examination of the ability of people to identify early changes of melanoma in computer-altered pigmented skin lesions. Arch Dermatol 1997;133:301-11.

16 Kiekbusch S, Hannich HJ, Isacsson A, Johannisson A, Lindholm LH, Sager E, et al. Impact of a cancer education multimedia device on public knowledge, attitudes, and behaviors: a controlled intervention study in Southern Sweden. Cancer Educ 2000;15:232-6.

17 Sefton E, Glazebrook C, Garrud P, Zaki I. Educating patients about malignant melanoma: computer-assisted learning in a pigmented lesion. Br J Dermatol 2000;142:66-71.

18 Bastuji-Garin S, Grob JJ, Grognard C, Grosjean F, Guillaume JC. Melanoma prevention: evaluation of a health education campaign for primary schools. Arch Dermatol 1999;135:936-40. [section 2.3.1] [section 7.9.3]

19 Helfand M, Mahon S, Eden K. Screening for skin cancer. Rockville (MD): Agency for Healthcare Research and Quality; 2001. Systematic evidence review No. 2. AHRQ publication No. 01-S002. [cited 16 May 2003]. Available from url: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowSection&rid=hstat3.chapter.711 [section 2.4.1] [section 2.4.2] [section 2.4.5]

20 Melia J, Harland C, Moss S, Eiser JR, Pendry L. Feasibility of targeted early detection for melanoma: a population-based screening study. Br J Cancer 2000;82:1605-9.

21 Katris P, Donovan RJ, Gray BN. The use of targeted and non-targeted advertising to enrich skin cancer screening samples. Br J Dermatol 1996;135:268-74.

22 Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003;97:639-43.

23 Marghoob AA, Schoenbach SP, Kopf AW, Orlow SJ, Nossa R, Bart RS. Large congenital melanocytic nevi and the risk for the development of malignant melanoma. Arch Dermatol 1996;132:170-5.

24 Swerdlow AJ, English JS, Qiao Z. The risk of melanoma in patients with congenital nevi: a cohort study. J Am Acad Dermatol 1995;32:595-9.

25 Harris V, Sandridge A, Black RJ, Brewster DH, Gould A. Cancer Registration Statistics Scotland, 1986 - 1995. Edinburgh: National Health Service in Scotland, Information and Statistics Division; 1998.

26 Carstairs V, Morris R. Deprivation and health in Scotland. Health Bull (Edinb) 1990;48:162-75.

27 International Agency for Research on Cancer. IARC monographs on the evaluation of the carcinogenic risk of chemical to humans. Volume 38: tobacco smoking. Lyon: The Agency; 1986.

28 MacKie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet 1993;341:1618-20.

29 MacKie RM, Hole D. Audit of public education campaign to encourage earlier detection of malignant melanoma. BMJ 1992;304:1012-5.

30 Melia J, Moss S, Coleman D, Frost T, Graham-Brown R, Hunter JAA, et al. The relation between mortality from malignant melanoma and early detection in the Cancer Research Campaign Mole Watcher Study. Br J Cancer 2001;85:803-7.

31 Ferrini RL, Perlman M, Hill L. American College of Preventive Medicine policy statement: screening for skin cancer. Am J Prev Med 1998;14:80-2.

32 Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999;17:3245-51.

33 MacKie RM, Andrew N, Lanyon WG, Connor JM. OMIM CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 1998;111:269-72.

34 Yakobson E, Shemesh P, Azizi E, Winkler E, Lassam N, Hogg D, et al. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. Eur J Hum Genet 2000;8:590-6.

35 Della Torre G, Pasini B, Frigerio S, Donghi R, Rovini D, Delia D, et al. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 2001;85:836-44.

36 Greene MH. The genetics of hereditary melanoma and nevi: 1998 update. Cancer 1999;86:1644-57.

37 Goldstein AM, Chidambaram A, Halpern A, Holly EA, Guerry IV D, Sagebiel R, et al. Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res 2002;12:51-5.

38 Kefford R, Bishop JN, Tucker M, Bressac-de Paillerets B, Bianchi-Scarra G, Bergman W, et al. Genetic testing for melanoma. Melanoma Genetics Consortium. Lancet Oncol 2002;3:653-4.

39 Healsmith MF, Bourke JF, Osborne JE, Graham-Brown RA. An evaluation of the revised seven-point checklist for the early diagnosis of cutaneous malignant melanoma. Br J Dermatol 1994;130:48-50.

40 Fitzpatrick TB, Rhodes AR, Sober AJ, Mihm MC. Primary malignant melanoma of the skin: the call for action to identify persons at risk; to discover precursor lesions; to detect early melanomas. Pigment Cell 1988;9:110-7.

41 Duff CG, Melsom D, Rigby HS, Kenealy JM, Townsend PL. A 6 year prospective analysis of the diagnosis of malignant melanoma in a pigmented-lesion clinic: even the experts miss malignant melanomas, but not often. Br J Plast Surg 2001;54:317-21. [section 3.2] [section 3.3]

42 Richard MA, Grob JJ, Avril MF, Delaunay M, Gouvernet J, Wolkenstein P, et al. Delays in diagnosis and melanoma prognosis (II): the role of doctors. Int J Cancer 2000:20;89:280-5. [section 3.2] [section 3.3]

43 Gerbert B, Maurer T, Berger T, Pantilat S, McPhee SJ, Wolff M, et al. Primary care physicians as gatekeepers in managed care. Primary care physicians’ and dermatologists’ skills at secondary prevention of skin cancer. Arch Dermatol 1996;132:1030-8.

44 Bafounta ML, Beauchet A, Aegerter P, Saiag P. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol 2001;137:1343-50.

45 Westerhoff K, McCarthy WH, Menzies SW. Increase in the sensitivity for melanoma diagnosis by primary care physicians using skin surface microscopy. Br J Dermatol 2000;143:1016-20.

46 Binder M, Schwarz M, Winkler A, Steiner A, Kaider A, Wolff K, et al. Epiluminescence microscopy. A useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch Dermatol
1995;131:286-91.

47 Benelli C, Roscetti E, Pozzo VD, Gasparini G, Cavicchini S. The dermoscopic versus the clinical diagnosis of melanoma. Eur J Dermatol 1999;9:470-6.

48 Maurer J, Knollmann FD, Schlums D, Garbe C, Vogl TJ, Bier J, et al. Role of high-resolution magnetic resonance imaging for differentiating melanin-containing skin tumors. Invest Radiol 1995;30:638-43.

49 Lassau N, Spatz A, Avril MF, Tardivon A, Margulis A, Mamelle G, et al. Value of high-frequency US for preoperative assessment of skin tumors. Radiographics 1997;17:1559-65.

50 Chwirot BW, Chwirot S, Redzinski J, Michniewicz Z. Detection of melanomas by digital imaging of spectrally resolved ultraviolet light-induced autofluorescence of human skin. Eur J Cancer 1998;34:1730-4.

51 Aitken JF, Pfitzner J, Battistutta D, O’Rourke PK, Green AC, Martin NG. Reliability of computer image analysis of pigmented skin lesions of Australian adolescents. Cancer 1996;78:252-7.

52 O’Donnell B, Dervan P, Codd M, Powell F, Lawlor D, O’Loughlin S. A clinicopathological correlation of 134 stage 1 and 79 non-invasive cutaneous melanomas presenting over a decade (1984-1993) at the Mater Misericordiae Hospital, Dublin. Ir J Med Sci 1998;167:132-5.

53 Lennon GM, Griffin M, O’Briain DS, Cassidy M, Caldwell M, Young M, et al. Malignant melanoma lately diagnosed. Ir Med J 1989;82:109-11.

54 Baccard M, Chevret S, Chemaly P, Morel P. Delay in diagnosing melanoma. A prospective study in 102 patients. Ann Dermatol Venereol 1997;124:601-6.

55 Oliveria SA, Christos PJ, Halpern AC, Fine JA, Barnhill RL, Berwick M. Patient knowledge, awareness, and delay in seeking medical attention for malignant melanoma. J Clin Epidemiol 1999;52:1111-6.

56 Richard MA, Grob JJ, Avril MF, Delaunay M, Gouvernet J, Wolkenstein P, et al. Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer 2000;89:271-9.

57 Franke W, Neumann NJ, Ruzicka T, Schulte KW. Plantar malignant melanoma — a challenge for early recognition. Melanoma Res 2000;10:571-6.

58 Bennett DR, Wasson D, MacArthur JD, McMillen MA. The effect of misdiagnosis and delay in diagnosis on clinical outcome in melanomas of the foot. J Am Coll Surg 1994;179:279-84.

59 Rampen FH, Rumke P, Hart AA. Patients’ and doctors’ delay in the diagnosis and treatment of cutaneous melanoma. Eur J Surg Oncol 1989;15:143-8.

60 Del Mar CB, Green AC, Battistutta D. Do public media campaigns designed to increase skin cancer awareness result in increased skin excision rates? Aust N Z J Public Health 1997;21:751-4.

61 Gerbert B, Bronstone A, Wolff M, Maurer T, Berger T, Pantilat S, et al. Improving primary care residents’ proficiency in the diagnosis of skin cancer. J Gen Intern Med 1998;13:91-7.

62 Calonje E. ACP best practice no 162. The histological reporting of melanoma. Association of Clinical Pathologists. J Clin Pathol 2000;53:587-90. [section 3.5] [section 3.7.1] [section 3.8.1] [section 4.1.1]

63 Griffiths RW, Briggs JC. Biopsy procedures, primary wide excisional surgery and long term prognosis in primary clinical stage I invasive cutaneous malignant melanoma. Ann R Coll Surg Engl 1985;67:75-8.

64 Lees VC, Briggs JC. Effect of initial biopsy procedure on prognosis in Stage I invasive cutaneous malignant melanoma: review of 1086 patients. Br J Surg 1991;78:1108-10.

65 Pariser RJ, Divers A, Nassar A. The relationship between biopsy technique and uncertainty in the histopathologic diagnosis of melanoma. Dermatol Online J 1999;5:4.

66 Lederman JS, Sober AJ. Does biopsy type influence survival in clinical stage I cutaneous melanoma? J Am Acad Dermatol 1985;13:983-7.

67 Witheiler DD, Cockerell CJ. Sensitivity of diagnosis of malignant melanoma: a clinicopathologic study with a critical assessment of biopsy techniques. Exp Dermatol 1992;1:170-5.

68 Bong JL, Herd RM, Hunter JA. Incisional biopsy and melanoma prognosis. J Am Acad Dermatol 2002;46:690-4.

69 Coleman WP 3rd, Davis RS, Reed RJ, Krementz ET. Links Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol 1980;6:476-9.

70 Mahendran RM, Newton–Bishop JA. Survey of UK current practice in the treatment of lentigo melanoma. Brit J Dermatol 2001;144:71-6.

71 Schmid-Wendtner MH, Brunner B, Konz B, Kaudewitz P, Wendtner CM, Peter RU, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000;43:477-82.

72 Dancuart F, Harwood AR, Fitzpatrick PJ. The radiotherapy of lentigo maligna and lentigo maligna melanoma of the head and neck. Cancer 1980;45:2279-83.

73 Harwood AR. Conventional radiotherapy in the treatment of lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1982;6:310-6.

74 Rosai J, editor. Ackerman’s Surgical Pathology. 8th ed. St Louis (MO): Mosby; 1996. [section 3.7.1] [section 3.11]

75 Cochran AJ, Elashoff D, Morton DL, Elashoff R. Individualized prognosis for melanoma patients. Hum Pathol 2000;31:327-31. [section 3.8.1] [section 3.8.2] [section 3.8.4] [section 3.8.6] [section 3.8.7] [section 3.8.8] [section 3.8.9] [section 3.8.11]

76 Clark WH Jr, Elder DE, Guerry D 4th, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904. [section 3.8.1] [section 3.8.2] [section 3.8.3] [section 3.8.4] [section 3.8.6] [section 3.8.7] [section 3.8.8] [section 3.8.9] [section 3.8.11]

77 Cascinelli N, Zurrida S, Galimberti V, Bartoli C, Bufalino R, Del Prato I, et al. Acral lentiginous melanoma. A histological type without prognostic significance. J Dermatol Surg Oncol 1994;20:817-22.

78 Quinn MJ, Crotty KA, Thompson JF, Coates AS, O’Brien CJ, McCarthy WH. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998:83;1128-35.

79 Thorn M, Ponten F, Bergstrom R, Sparen P, Adami HO. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 1994;86:761-9.

80 Tralongo V, Daniele E, Leonardi V, Rodolico V. Prognostic value of clinicopathologic variables and DNA ploidy in stage I cutaneous malignant melanoma. Oncol Rep 1998;5:1095-8.

81 Spatz A, Shaw HM, Crotty KA, Thompson JF, McCarthy SW. Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (> 5 mm). Histopathology 1998;33:406-13.

82 Guerry D 4th, Synnestvedt M, Elder DE, Schultz D. Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 1993;100:342S-5S. [section 3.8.3] [section 7.2]

83 Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-8.

84 Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996;78:427-32. [section 3.8.4] [section 3.8.6]

85 Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000;88:1484-91.

86 Buttner P, Garbe C, Bertz J, Burg G, d’Hoedt B, Drepper H, et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark’s level for prognostic classification. Cancer
1995;75:2499-506.

87 Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology 1990;17:389-95. [section 3.8.5] [section 3.8.9]

88 Gershenwald JE, Buzaid AC, Ross MI. Classification and staging of melanoma. Clin Lab Med 2000;20:785-815. [section 3.8.5] [section 3.8.10]

89 Day CL Jr, Mihm MC Jr, Lew RA, Harris MN, Kopf AW, Fitzpatrick TB, et al. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg 1982;195:35-43.

90 Massi D, Borgognoni L, Franchi A, Martini L, Reali UM, Santucci M. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors. Melanoma Res 2000;10:153-64. [section 3.8.2] [section 3.8.7] [section 3.8.10]

91 Borgstein PJ, Meijer S, van Diest PJ. Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol 1999;6:315-21.

92 Aitchison TC, Sirel JM, Watt DC, MacKie RM. Prognostic trees to aid prognosis in patients with cutaneous malignant melanoma. Scottish Melanoma Group. BMJ 1995;311:1536-9.

93 Cook MG. Diagnostic discord with melanoma. J Pathol 1997;182:247-9.

94 Corona R, Mele A, Amini M, De Rosa G, Coppola G, Piccardi P, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 1996;14:1218-23.

95 Weinstock MA, Barnhill RL, Rhodes AR, Brodsky GL. Reliability of the histopathologic diagnosis of melanocytic dysplasia. The Dysplastic Nevus Panel. Arch Dermatol 1997;133:953-8.

96 Cochran AJ. Sentinel lymph node pathology. In: Kirkham N, Lemoine NR, editors. Progress in pathology volume 5. London: Greenwich Medical Media; 2001.

97 Rao UN, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol 2002;8:2053-7.

98 ADASP recommendations for processing and reporting lymph node specimens submitted for evaluation of metastatic disease. Am J Surg Pathol 2001;25:961-3.

99 Cochran AJ. Surgical pathology remains pivotal in the evaluation of ‘sentinel’ lymph nodes. Am J Surg Pathol 1999;23:1169-72.

100 Gutzmer R, Kaspari M, Brodersen JP, Mommert S, Volker B, Kapp A, et al. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies. Histopathology 2002;41:510-8.

101 Urist MM, Balch CM, Soong S, Shaw HM, Milton GW, Maddox WA. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 1985;55:1398-402.

102 Welvaart K, Hermans J, Zwaveling A, Ruiter DJ. Prognoses and surgical treatment of patients with stage I melanomas of the skin: a retrospective analysis of 211 patients. J Surg Oncol 1986;31:79-86.

103 Milton GW, Shaw HM, McCarthy WH. Resection margins for melanoma. Aust N Z J Surg 1985;55:225-6.

104 Taylor BA, Hughes LE. A policy of selective excision for primary cutaneous malignant melanoma. Eur J Surg Oncol 1985;11:7-13.

105 Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 melanoma. N Engl J Med 1988;318:1159-62.

106 Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. Efficacy of 2-melanoma surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262-9.

107 Cohn-Cedarmark G, Rutquist LE, Andersson R, Breivald M, Ingvar C, Johansson H, et al. Long term results of a randomized study by the Swedish melanoma study group on 2 melanoma versus 5 melanoma resection margins for patients with cutaneous melanoma with a tumour thickness of 0.8-2.0mm. Am Cancer Soc 2000;89:1495-501.

108 Ringborg U, Andersson R, Eldh J, Glaumann B, Hafstrom L, Jacobsson S, et al. Resection margins of 2 versus 5 melanoma for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 1996;77:1809-14.

109 Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol 1998;5:322-8.

110 Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48. [section 3.8.4] [section 3.8.5] [section 3.8.6] [section 3.8.7] [section 3.8.10] [section 4.1] [section 4.2] [section 5.2]

111 Olsen G. Removal of fascia: cause of more frequent metastases of malignant melanoma of the skin to regional lymph nodes. Cancer 1964;17:1159-63.

112 Kenady DE, Brown BW, McBride CM. Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and survival rates. Surgery 1982;92:615-8.

113 Balch CM, Soong SJ, Gershwinwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34. [section 4.3] [section 4.3.2]

114 Stankard C, Cruse CW, Cox C, Wells KE, King J, Reintgen DS. The concept of lymph node dissections in patients with malignant melanoma. Ann Plast Surg 1992;28:33-8.

115 Balch CM. Surgical management of melanoma: results of prospective randomised trials. Ann Surg Oncol 1998;5:301-9.

116 Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Stage I melanoma of the limbs. Immediate versus delayed node dissection. Tumori 1980;66:373-96.

117 McCarthy WH, Shaw HM, Cascinelli N, Santinami M, Belli F. Elective lymph node dissection for melanoma: two perspectives. World J Surg 1992;16:203-13. [section 4.3] [section 7.5.2]

118 Woods JE. Management of malignant melanoma of the head and neck. Mayo Clin Proc 1989;64:861-3. [section 4.3] [section 4.3.2]

119 Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981;193:377-88.

120 Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg 1991;214:627-36. [section 4.3] [section 4.3.2]

121 Roberts DL, Anstey AV, Barlow RJ, Cox NH, Newton Bishop JA, Corrie PG. UK guidelines for the management of cutaneous melanoma. Br J Dermatol 2002;146:7-17.

122 Jonk A, Kroon BBR, Mooi WJ, et al. Value of therapeutic neck dissection in patients with melanoma. Diag Oncol 1993;3:268-70.

123 O’Brien CJ, Gianoutsos MP, Morgan MJ. Neck dissection for cutaneous malignant melanoma. World J Surg 1992 16:222-6.

124 Sterne GD, Murray DS, Grimley RP. Ilioinguinal block dissection for malignant melanoma. Br J Surg 1995;82:1057-9.

125 Karakousis CP, Driscoll DL. Groin dissection in malignant melanoma. Br J Surg 1994;81:1771-4.

126 Drepper H, Kohler CO, Bastian B, Breuninger H, Brocker EB, Gohl J, et al. Benefit of elective lymph node dissection in sub groups of melanoma patients. Results of a multicentre study of 3616 patients. Cancer 1993;72:741-9.

127 McCarthy WH, Shaw HM, Milton GW. Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma. Surg Gynecol Obstet 1985;161:575-80.

128 Hein DW, Moy RL. Elective lymph node dissection in stage I malignant melanoma: a meta-analysis. Melanoma Res 1992;2:273-7.

129 Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986;61:697-705.

130 Veronesi U, Adamus J, Bandiera DC, Brennhovd O, Caceres E, Cascinelli N, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-30.

131 Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-66.

132 Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000;7:87-97.

133 Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.

134 Karakousis CP, Grigoropoulos P. Sentinel node biopsy before and after wide excision of the primary melanoma.Ann Surg Oncol 1999;6:785-9. [section 4.3.5] [section 7.9.3]

135 Bostick P, Essner R, Glass E, Kelley M, Sarantou T, Foshag LJ, et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg 1999;134:43-9.

136 Gershenwald JE, Tseng CH, Thompson W, Mansfield PF, Lee JE, Bouvet M, et al. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 1998;124:203-10.

137 Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-65.

138 Morton DL. Sentinel lymphadenectomy for patients with clinical stage I melanoma. J Surg Oncol 1997;66:267-9.

139 Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-67.

140 Clary BM, Mann B, Brady MS, Lewis JJ, Coit DG. Early recurrence after lymphatic mapping and sentinel node biopsy in patients with primary extremity melanoma: a comparison with elective lymph node dissection. Ann Surg Oncol 2001;8:328-37.

141 Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 2000;7:160-5.

142 Krementz ET, Carter RD, Sutherland CM, Campbell M. The use of regional chemotherapy in the management of malignant melanoma. World J Surg 1979;3:289-304.

143 Lejeune FJ. Isolation perfusion of the limbs for malignant melanoma. In: 38th Clinical Conference, Advances in the Biology and Clinical Management of Melanoma. February 21-24, Houston, Texas. Houston (TX): MD Anderson Cancer Center; 1995. p. 13-14.

144 Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998;16:2906-12.

145 Lienard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999;9:491-502.

146 Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996;83:1319-28.

147 Lienard D, Eggermont AM, Kroon BB, Schraffordt Koops H, Lejeune FJ. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol 1998;14:202-9.

148 Hill S, Thomas JM. Treatment of cutaneous metastases from malignant melanoma using the carbon-dioxide laser. Eur J Surg Oncol 1993;19:173-7.

149 Lingam MK, McKay AJ. Carbon dioxide laser ablation as an alternative treatment for cutaneous metastases from malignant melanoma. Br J Surg 1995;82:1346-8.

150 Hill S, Thomas JM. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996;83:509-12.

151 Terhune MH, Swanson N, Johnson TM. Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol 1998;134:569-72.

152 Tregnaghi A, De Candia A, Calderone M, Cellini L, Rossi CR, Talenti E, et al. Ultrasonographic evaluation of superficial lymph node metastases in melanoma. Eur J Radiol 1997;24:216-21.

153 Bossi MC, Sanvito S, Lovati E, De Fiori E, Testori A, Bellomi M. Role of high resolution color-Doppler US of the sentinel node in patients with stage I melanoma [Italian]. Radiol Med (Torino) 2001;102:357-62.

154 Buzaid AC, Sandler AB, Mani S, Curtis AM, Poo WJ, Bolognia JL, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993;11:638-43.

155 Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with local- regional metastases of melanoma. J Clin Oncol 1995;13:2104-8. [section 5.1.3] [section 7.9.3]

156 Huang CL, Provost N, Marghoob AA, Levin L, Bart RS. Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol 1998;39:451-63. [section 5.2] [section 7.9.1]

157 Finck SJ, Guiliano AE, Morton DL. LDH and melanoma. Cancer 1983;51:840-3. [section 5.2] [section 7.9.1]

158 Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913-6.

159 Corry J, Smith JG, Bishop M, Ainslie J. Nodal radiation therapy for metastatic melanoma. Int J Radiat Oncol Biol Phys 1999;44:1065-9.

160 Stevens G, Thompson JF, Firth I, O’Brien CJ, McCarthy WH, Quinn MJ. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000;88:88-94.

161 O’Brien CJ, Petersen-Schaefer K, Stevens GN, Bass PC, Tew P, Gebski VJ, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997;19:589-94.

162 Hietanen T, Nieminen S, Ekfors T, Nordman E. Elective treatment of regional lymph nodes in malignant melanoma. Strahlentherapie 1985;161:1-4.

163 Fenig E, Eidelvich E, Njuguna E, Katz A, Gutman H, Sulkes A, et al. Role of radiation therapy in the management of cutaneous malignant melanoma. Am J Clin Oncol 1999;22:184-6.

164 Ang KK, Peters LJ, Weber RS, Morrison WH, Frankenthaler RA, Garden AS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994;30:795-8.

165 Creagan ET, Cupps RE, Ivins JC, Pritchard DJ, Sim FH, Soule EH, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer 1978;42:2206-10.

166 Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM Jr, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776-83.

167 Meyskens FL Jr, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst 1995;87:1710-3.

168 Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.

169 Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:1905-10.

170 Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998;16:1425-9.

171 Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.

172 Cameron DA, Cornbleet MC, Mackie RM, Hunter JA, Gore M, Hancock B, et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001;84:1146-9.

173 Eggermont AM, Keilholz U, Testori A, Cook M, Lienard D, Ruiter DJ. The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer. Ann Surg Oncol 2001;8:38S-40S.

174 Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001;358:866-9.

175 Hancock BW, Harris S, Wheatley K, Gore M. Adjuvant interferon-alpha in malignant melanoma: current status. Cancer Treat Rev 2000;26:81-9.

176 Wallack MK, Sivanandham M, Balch, Urist MM, Bland KI, Murray D, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69-77.

177 Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002;20:4181-90.

178 Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80

179 Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol 1999;140:249-54. [section 7.1] [section 7.2] [section 7.4] [section 7.5.1] [section 7.5.2] [section 7.5.3] [section 7.8] [section 7.9]

180 Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O’Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995;274:1703-5. [section 7.1] [section 7.3] [section 7.9] [section 7.9.1] [section 7.9.3]

181 Basseres N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995;19:199-203. [section 7.1] [section 7.3] [section 7.5.1] [section 7.5.2] [section 7.5.3] [section 7.9] [section 7.9.1] [section 7.9.3] [section 11.2.5]

182 Bastien M, Tessier MH, Legoux B, Litoux P, Bureau B, Dreno B. Usefulness of paraclinical follow-up in stage I melanoma. Arch Dermatol 1997;133:1462-3. [section 7.1] [section 7.3] [section 7.9.1]

183 Mooney MM, Kulas M, McKinley B, Michalek AM, Kraybill WG. Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma. Ann Surg Oncol 1998;5:54-63. [section 7.1] [section 7.3] [section 7.9] [section 7.9.3]

184 Kelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol 1985;13:756-60. [section 7.1] [section 7.3] [section 7.4] [section 7.5.1] [section 7.5.3]

185 McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow up. Surg Gynecol Obstet 1988;166:497-502. [section 7.1] [section 7.3] [section 7.4] [section 7.5.1] [section 7.5.2] [section 7.5.3] [section 7.8]

186 Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow up in stage 1 cutaneous malignant melanoma: an audit. Clin Oncol 1993;5:174-80. [section 7.1] [section 7.3] [section 7.5.1] [section 7.5.2] [section 7.5.3] [section 7.9]

187 Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003;21:520-9. [section 7.1] [section 7.3] [section 7.5.1] [section 7.5.2] [section 7.9] [section 7.9.1] [section 7.9.3]

188 Martini L, Brandini P, Chiarugi C, Reali UM. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow up schedule. Tumori 1994;80:188-97. [section 7.3] [section 7.4] [section 7.5.1] [section 7.5.2] [section 7.5.3]

189 Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993;91:94-8. [section 7.3] [section 7.4]

190 Tahery DP, Moy RL. Lack of predictive factors in late recurrence of stage 1 melanoma. Int J Dermatol 1992;31;629-31.

191 McEwan L, Smith JG, Matthews JP. Late recurrence of localized cutaneous melanoma: its influence on follow up policy. Plast Reconstr Surg 1990;86:527-34.

192 Pearlman NW, Takach TJ, Robinson WA, Ferguson J, Cohen AL. A case-control study of late recurrence of malignant melanoma. Am J Surg 1992;164:458-61.

193 McCarthy WH, Shaw HM, McCarthy SW, Rivers JK, Thompson JF. Cutaneous melanomas that defy conventional prognostic indicators. Semin Oncol 1996;23:709-13.

194 Sylaidis P, Gordon D, Rigby H, Kenealy J. Follow-up requirements for thick cutaneous melanoma. Br J Plast Surg 1997;50:349-53.

195 Burden AD, Vestey JP, Sirel JP, Aitcheson TC, Hunter JAA, MacKie RM. Multiple primary melanoma: risk factors and prognostic implications. BMJ 1994;309:375.

196 Jillella A, Mani S, Nair B, Poo WJ, Bolognia J, Ariyan S, et al. The role for close follow-up of melanoma patients with AJCC stages l-lll: a preliminary analysis [abstract]. Proc Am Soc Clin Oncol 1995;14:413.

197 Ruark DS, Shaw HM, Ingvar C, McCarthy WH, Thompson JF. Who detects the first recurrence in stage I cutaneous melanoma: patient or doctor? Melanoma Res 1993;3:44.

198 Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg 1995;221:566-9. [section 7.9] [section 7.9.1] [section 7.9.3]

199 Franzke A, Probst-Kepper M, Buer J. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 1998;78:40-5. [section 7.9] [section 7.9.1]

200 Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993;72:3091-8.

201 Heimdal K, Hannisdal E, Gundersen S. Regression analyses of prognostic factors on metastatic malignant melanoma. Eur J Cancer Clin Oncol 1989;25:1219-23.

202 Brochez L, Naeyaert JM. Serological markers for melanoma. Br J Dermatol 2000;143:256-68. [section 5.2] [section 7.9.2]

203 Bastien M, Tessier MH, Legoux B, Litoux P, Bureau B, Dreno B. Usefulness of paraclinical follow-up in stage I melanoma [letter]. Arch Dermatol 1997;133:1462-3.

204 Kuvshinoff BW, Kurtz K, Coit DG. Computed Tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997;4:252-8.

205 Johnson TM, Fader DJ, Chang AE, Yahanda A, Smith JW 2nd, Hamlet KR, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol 1997;4:396-402.

206 Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782-93. [section 8] [section 8.1]

207 Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983;1:126-34.

208 Brand CU, Ellwanger U, Stroebel W, Meier F, Schlagenhauff B, Rassner G, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer
1997;79:2345-53. [section 8] [section 8.1]

209 Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma. Surgery 1994;115:295-302.

210 Wong JH, Skinner KA, Kim KA, Foshag LJ, Morton DL. The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery 1993;113:389-94.

211 Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma (Cochrane Review) In: The Cochrane Library, Issue 4, 2002. Oxford: Update Software.

212 Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001;11:75-81.

213 Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51.

214 Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.

215 Rusthoven JJ. The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma. Eur J Cancer 1998 34:S31-6.

216 Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:1743-51.

217 Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 1999;85:1979-84.

218 Hernberg M, Pyrhonen S, Muhonen T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999;22:145-54.

219 Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001;84:1036-42.

220 Geara FB, Ang KK. Radiation therapy for malignant melanoma. Surg Clin North Am 1996;76:1383-98. [section 8.3.1] [section 8.3.4]

221 Overgaard J. Radiation treatment of malignant melanoma. Int J Radiat Oncol Biol Phys 1980;6:41-4.

222 Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N, et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int J Radiat Oncol Biol Phys 1998;42:161-7.

223 Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 1998;47:233-40.

224 Ratanatharathorn V, Powers WE, Moss WT, Perez CA. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 1999;44:1-18.

225 Kirova YM, Chen J, Rabarijaona LI, Piedbois Y, Le Bourgeois JP. Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 1999;9:611-3.

226 Levack P, Collie D, Gibson A, Graham J, Grant R, Hurman D, et al. A prospective audit of the diagnosis, management and outcome of malignant cord compression. Edinburgh: Scottish Executive Department of Health, Clinical Resources and Audit Group; 2001. [cited 16 May 2003]. Available from url: http://www.show.scot.nhs.uk/crag/committees/CEPS/reports/F%20Report%20copy%206-2-02.PDF

227 Scottish Executive Department of Health. Scottish referral guidelines for suspected cancer. Edinburgh: The Department; 2002. [cited 16 May 2003]. Available from url: http://www.show.scot.nhs.uk/sehd/cancerinscotland/Documents/Scottish%20Referral%20Guidelines%20for%20suspected%20cancer.pdf

228 Wronski M, Arbit EA. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 2000;93:9-18.

229 Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999;43:795-803.

230 Gupta G, Robertson AG, MacKie RM. Cerebral metastases of cutaneous melanoma. Br J Cancer 1997;76:256-9.

231 Ewend MG, Carey LA, Brem H. Treatment of melanoma metastases in the brain. Semin Surg Oncol 1996;12:429-35.

232 Grob JJ, Regis J, Laurans R, Delaunay M, Wolkenstein P, Paul K, et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancerologie Cutanee. Eur J Cancer 1998;34:1187-92.

233 General Medical Council. Tomorrow’s doctors. Recommendations on undergraduate medical education. London: The Council; 2002. [cited 16 May 2003]. Available from url: http://www.gmc-uk.org/med_ed/tomdoc.htm

234 Clinical Standards Board for Scotland. Clinical standards. Specialist palliative care. Revised ed. Edinburgh: The Board; 2002. [cited 16 May 2003]. Available from url: http://www.clinicalstandards.org/pdf/finalstand/SPC.pdf

235 Scottish Intercollegiate Guidelines Network (SIGN). Control of pain in patients with cancer. Edinburgh: SIGN; 2000. (SIGN guideline no. 44).

236 Addington-Hall JM, MacDonald LD, Anderson HR, Chamberlain J, Freeling P, Bland JM, et al. Randomised controlled trial of effects of coordinating care for terminally ill cancer patients. BMJ 1992;305:1317-22.

237 Raftery JP, Addington-Hall JM, MacDonald LD, Anderson HR, Bland JM, Chamberlain J, et al. A randomized controlled trial of the cost-effectiveness of a district co-ordinating service for terminally ill cancer patients. Palliat Med 1996;10:151-61.

238 Jordhoy MS, Fayers P, Saltnes T, Ahlner-Elmqvist M, Jannert M, Kaasa S. A palliative-care intervention and death at home: a cluster randomised trial. Lancet 2000;356:888-93.

239 Hearn J, Higginson IJ. Do specialist palliative care teams improve outcomes for cancer patients? A systematic literature review. Palliat Med 1998;12:317-32.

240 Wong JH, Sterns EE, Kopald KH, Nizze JA, Morton DL. Prognostic significance of pregnancy in stage I melanoma. Arch Surg 1989;124:1227-30.

241 Slingluff CL Jr, Reintgen DS, Vollmer RT, Seigler HF. Malignant melanoma arising during pregnancy. A study of 100 patients. Ann Surg 1990;211:552-7.

242 MacKie RM, Bufalino R, Morabito A, Sutherland C, Cascinelli N. Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme. Lancet 1991;337:653-5.

243 Travers RL, Sober AJ, Berwick M, Mihm MC Jr, Barnhill RL, Duncan LM. Increased thickness of pregnancy-associated melanoma. Br J Dermatol 1995;132:876-83.

244 Potter JF, Schoeneman M. Metastasis of maternal cancer to the placenta and fetus. Cancer 1970;25:380-8.

245 Baergen RN, Johnson D, Moore T, Benirschke K. Maternal melanoma metastatic to the placenta: a case report and review of the literature. Arch Pathol Lab Med 1997;121:508-11.

246 Ferreira CM, Maceira JM, Coelho JM. Melanoma and pregnancy with placental metastases. Report of a case. Am J Dermatopathol 1998;20:403-7.

247 Grin CM, Driscoll MS, Grant-Kels JM.The relationship of pregnancy, hormones, and melanoma. Semin Cutan Med Surg 1998;17:167-71.

248 Shiu MH, Schottenfeld D, Maclean B, Fortner JG. Adverse effect of pregnancy on melanoma: a reappraisal. Cancer 1976;37:181-7. [section 9.1] [section 9.2]

249 Gefeller O, Hassan K, Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol 1998;138:122-4.

250 Danforth DN Jr, Russell N, McBride CM. Hormonal status of patients with primary malignant melanoma: a review of 313 cases. South Med J 1982;75:661-4.

251 Lederman JS, Lew RA, Koh HK, Sober AJ. Influence of estrogen administration on tumor characteristics and survival in women with cutaneous melanoma. J Natl Cancer Inst 1985;74:981-5. [section 9.2] [section 9.3]

252 Osterlind A, Tucker MA, Stone BJ, Jensen OM.The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer 1988;42:821-4. [section 9.2] [section 9.3]

253 Stevens RG, Lee JA, Moolgavkar SH. No association between oral contraceptives and malignant melanomas. N Engl J Med 1980;302:966.

254 Karagas MR, Stukel TA, Dykes J, Miglionico J, Greene MA, Carey M, et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 2002;86:1085-92.

255 Zanetti R, Franceschi S, Rosso S, Bidoli E, Colonna S. Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors. Int J Epidemiol 1990;19:522-6.

256 Le MG, Cabanes PA, Desvignes V, Chanteau MF, Mlika N, Avril MF. Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women. Cancer Causes Control 1992;3:199-205.

257 Smith MA, Fine JA, Barnhill RL, Berwick M. Hormonal and reproductive influences and risk of melanoma in women. Int J Epidemiol 1998;27:751-7.

258 Brandberg Y, Bergenmar M, Bolund C, Michelson H, Mansson-Brahme E, Ringborg U, et al. Information to patients with malignant melanoma: a randomised group study. Patient Educ Couns 1994;23:97-105. [section 3.8.2] [section 10.3] [section 10.4]

259 Fawzy NW. A psychoeducational nursing intervention to enhance coping and affective state in newly diagnosed malignant melanoma patients. Cancer Nurs 1995;18:427-38. [section 10.3] [section 10.4]

260 Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol 1999;17:2256-63. [section 10.3] [section 10.4]

261 Brandberg Y, Bergenmar M, Michelson H, Mansson-Brahme E, Sjoden PO. Six-month follow-up of effects of an information programme for patients with malignant melanoma. Patient Educ Couns 1996;28:201-8.

262 Scottish Executive Department of Health. Introduction of managed clinical networks within the NHS in Scotland. (NHS MEL(1999)10). Edinburgh: The Department; 1999. [cited 16 May 2003]. Available from url: http://www.show.scot.nhs.uk/sehd/mels/1999_10.htm

263 Girgis A, Clarke P, Burton RC, Sanson-Fisher RW. Screening for melanoma by primary health care physicians: a cost-effectiveness analysis. J Med Screen 1996;3:47-53.

264 Freedberg KA, Geller AC, Miller DR, Lew RA, Koh HK. Screening for malignant melanoma: a cost-effectiveness analysis. J Am Acad Dermatol 1999;41:738-45.

265 Beddingfield FC. Melanoma: a decision analysis to estimate the effectiveness and cost-effectiveness of screening and an analysis of the relevant epidemiology of the disease [dissertation]. Santa Monica (CA): RAND; 2002. [cited 16 May 2003]. Available from url: http://www.rand.org/publications/RGSD/RGSD167/

266 Brobeil A, Cruse CW, Messina JL, Glass LF, Haddad FF, Berman CG, et al. Cost analysis of sentinel lymph node biopsy as an alternative to elective lymph node dissection in patients with malignant melanoma. Surg Oncol Clin N Am 1999;8:435-45,viii.

267 Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737-43.

268 von Schulthess GK, Steinert HC, Dummer R, Weder W. Cost-effectiveness of whole-body PET imaging in non-small cell lung cancer and malignant melanoma. Acad Radiol 1998;5:S300-2.

269 Ghersi D, Howard K, Irwig L, Salkeld G, Simes J. Positron emission tomography. Canberra: Medicare Services Advisory Committee; 2001. [cited 16 May 2003]. Available from url: http://www.health.gov.au/msac/pdfs/msacref02.pdf

270 Messori A, Becagli P, Trippoli S, Tendi E. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer 1997;33:1373-9.

271 Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997;15:2351-8.

272 Gonzalez-Larriba JL, Serrano S, Alvarez-Mon M, Camacho F, Casado MA, Diaz-Perez JL, et al. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur J Cancer 2000;36:2344-52.

273 Shepherd J, Milne R. The use of interferon alfa in the treatment of metastatic cutaneous melanoma. Southampton: Wessex Institute for Health Research and Development; 1999. Development and evaluation committee report No. 99.

274 Lafuma A, Dreno B, Delaunay M, Emery C, Fagnani F, Hieke K, et al. Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma. Eur J Cancer 2001;37:369-75.

275 Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients—monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002;87:151-7.

276 Scottish Executive Health Department. Cancer in Scotland: action for Change. Edinburgh: The Executive; 2001. [cited 16 May 2003]. Available from url: http://www.scotland.gov.uk/library3/health/csac-00.asp

277 MacKie RM, Bray CA, Hole DJ, Morris A, Nicolson M, Evans A, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002;360:587-91.